You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 3, 2024

Investigational Drug Information for Surufatinib


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug Surufatinib?

Surufatinib is an investigational drug.

There have been 61 clinical trials for Surufatinib. The most recent clinical trial was a Phase 2 trial, which was initiated on December 7th 2015.

The most common disease conditions in clinical trials are Carcinoma, Neuroendocrine Tumors, and Small Cell Lung Carcinoma. The leading clinical trial sponsors are Hutchison Medipharma Limited, Sun Yat-sen University, and Fujian Cancer Hospital.

There are two US patents protecting this investigational drug and twenty-one international patents.

Recent Clinical Trials for Surufatinib
TitleSponsorPhase
Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic CancerFudan UniversityPhase 1/Phase 2
Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic CancerShanghai Zhongshan HospitalPhase 1/Phase 2
Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung CancerHunan Cancer HospitalPhase 1/Phase 2

See all Surufatinib clinical trials

Clinical Trial Summary for Surufatinib

Top disease conditions for Surufatinib
Top clinical trial sponsors for Surufatinib

See all Surufatinib clinical trials

US Patents for Surufatinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Surufatinib ⤷  Try a Trial Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use Hutchison MediPharma Limited (Shanghai, CN) ⤷  Try a Trial
Surufatinib ⤷  Try a Trial Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use Hutchison Medipharma Limited (Shanghai, CN) ⤷  Try a Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Surufatinib

Drugname Country Document Number Estimated Expiration Related US Patent
Surufatinib Australia AU2010321366 2029-11-23 ⤷  Try a Trial
Surufatinib Brazil BR112012012138 2029-11-23 ⤷  Try a Trial
Surufatinib Canada CA2781066 2029-11-23 ⤷  Try a Trial
Surufatinib China CN102070618 2029-11-23 ⤷  Try a Trial
Surufatinib China CN102648194 2029-11-23 ⤷  Try a Trial
Surufatinib Denmark DK2504331 2029-11-23 ⤷  Try a Trial
Surufatinib European Patent Office EP2504331 2029-11-23 ⤷  Try a Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.